• 제목/요약/키워드: Brain:tumor

검색결과 890건 처리시간 0.033초

Pheochromocytoma with Brain Metastasis: A Extremely Rare Case in Worldwide

  • Cho, Yun Seong;Ryu, Hyang Joo;Kim, Se Hoon;Kang, Seok-Gu
    • Brain Tumor Research and Treatment
    • /
    • 제6권2호
    • /
    • pp.101-104
    • /
    • 2018
  • Pheochromocytoma (PCC) is a neuroendocrine tumor that mainly arises from the medulla of the adrenal gland. Some PCCs become malignant and metastasize to other organs. For example, it typically involves skeletal system, liver, lung, and regional lymph nodes. However, only a few cases of PCC with brain metastasis have been reported worldwide. We report a case of metastatic brain tumor from PCC in South Korea in 2016. A 52-year-old man presented with headache, dizziness and motor aphasia. He had a medical history of PCC with multi-organ metastasis, previously underwent several operations, and was treated with chemotherapy and radiotherapy. Brain MRIs showed a brain tumor on the left parietal lobe. Postoperative pathology confirmed that the metastatic brain tumor derived from malignant PCC. This is the first report PCC with brain metastasis in South Korea.

Recent Advancement of the Molecular Diagnosis in Pediatric Brain Tumor

  • Bae, Jeong-Mo;Won, Jae-Kyung;Park, Sung-Hye
    • Journal of Korean Neurosurgical Society
    • /
    • 제61권3호
    • /
    • pp.376-385
    • /
    • 2018
  • Recent discoveries of brain tumor-related genes and fast advances in genomic testing technologies have led to the era of molecular diagnosis of brain tumor. Molecular profiling of brain tumor became the significant step in the diagnosis, the prediction of prognosis and the treatment of brain tumor. Because traditional molecular testing methods have limitations in time and cost for multiple gene tests, next-generation sequencing technologies are rapidly introduced into clinical practice. Targeted sequencing panels using these technologies have been developed for brain tumors. In this article, focused on pediatric brain tumor, key discoveries of brain tumor-related genes are reviewed and cancer panels used in the molecular profiling of brain tumor are discussed.

Enhanced CNN Model for Brain Tumor Classification

  • Kasukurthi, Aravinda;Paleti, Lakshmikanth;Brahmaiah, Madamanchi;Sree, Ch.Sudha
    • International Journal of Computer Science & Network Security
    • /
    • 제22권5호
    • /
    • pp.143-148
    • /
    • 2022
  • Brain tumor classification is an important process that allows doctors to plan treatment for patients based on the stages of the tumor. To improve classification performance, various CNN-based architectures are used for brain tumor classification. Existing methods for brain tumor segmentation suffer from overfitting and poor efficiency when dealing with large datasets. The enhanced CNN architecture proposed in this study is based on U-Net for brain tumor segmentation, RefineNet for pattern analysis, and SegNet architecture for brain tumor classification. The brain tumor benchmark dataset was used to evaluate the enhanced CNN model's efficiency. Based on the local and context information of the MRI image, the U-Net provides good segmentation. SegNet selects the most important features for classification while also reducing the trainable parameters. In the classification of brain tumors, the enhanced CNN method outperforms the existing methods. The enhanced CNN model has an accuracy of 96.85 percent, while the existing CNN with transfer learning has an accuracy of 94.82 percent.

뇌종양 환자의 불확실성 개념분석 (Concept Analysis of Uncertainty in Brain Tumor Patients)

  • 김지현;양남영;전미양
    • 가정∙방문간호학회지
    • /
    • 제30권1호
    • /
    • pp.84-95
    • /
    • 2023
  • Purpose: This study aimed to clarify the concept of uncertainty in brain tumor patients. Methods: We used the Walker and Avant's concept analysis method. We searched RISS, MEDLINE, CINAHL, and EMBASE for published articles in Korean and English from January 2002 to December 2022. After applying the inclusion and exclusion criteria, 27 articles were selected for the final analysis. Result: "Uncertainty in brain tumor" was defined as a state in which related clues during the process of experiencing a disease after brain tumor diagnosis are unclear or difficult to understand, new experiences different from before, or a condition in which it is difficult to judge fragmentarily. Moreover, the empirical criteria for the attributes of uncertainty in brain tumor patients were ambiguity of the disease process, diversity of information, unpredictability of prognosis, and complexity of management. Conclusion: Brain tumor patients with uncertainty require strategic technology development so that brain tumor patients, their families, and health care providers can use reasonable coping methods.

Repeat Stereotactic Radiosurgery for Recurred Metastatic Brain Tumors

  • Kim, In-Young;Jung, Shin;Jung, Tae-Young;Moon, Kyung-Sub;Jang, Woo-Youl;Park, Jae-Young;Song, Tae-Wook;Lim, Sa-Hoe
    • Journal of Korean Neurosurgical Society
    • /
    • 제61권5호
    • /
    • pp.633-639
    • /
    • 2018
  • Objective : We investigated the outcomes of repeat stereotactic radiosurgery (SRS) for metastatic brain tumors that locally recurred despite previous SRS, focusing on the tumor control. Methods : A total of 114 patients with 176 locally recurring metastatic brain tumors underwent repeat SRS after previous SRS. The mean age was 59.4 years (range, 33 to 85), and there were 68 male and 46 female patients. The primary cancer types were non-small cell lung cancer (n=67), small cell lung cancer (n=12), gastrointestinal tract cancer (n=15), breast cancer (n=10), and others (n=10). The number of patients with a single recurring metastasis was 95 (79.8%), and another 19 had multiple recurrences. At the time of the repeat SRS, the mean volume of the locally recurring tumors was 5.94 mL (range, 0.42 to 29.94). We prescribed a mean margin dose of 17.04 Gy (range, 12 to 24) to the isodose line at the tumor border primarily using a 50% isodose line. Results : After the repeat SRS, we obtained clinical and magnetic resonance imaging follow-up data for 84 patients (73.7%) with a total of 108 tumors. The tumor control rate was 53.5% (58 of the 108), and the median and mean progression-free survival (PFS) periods were 246 and 383 days, respectively. The prognostic factors that were significantly related to better tumor control were prescription radiation dose of 16 Gy (p=0.000) and tumor volume less than both 4 mL (p=0.001) and 10 mL at the repeat SRS (p=0.008). The overall survival (OS) periods for all 114 patients after repeat SRS varied from 1 to 56 months, and median and mean OS periods were 229 and 404 days after the repeat SRS, respectively. The main cause of death was systemic problems including pulmonary dysfunction (n=58, 51%), and the identified direct or suspected brain-related death rate was around 20%. Conclusion : The tumor control following repeat SRS for locally recurring metastatic brain tumors after a previous SRS is relatively lower than that for primary SRS. However, both low tumor volume and high prescription radiation dose were significantly related to the tumor control following repeat SRS for these tumors after previous SRS, which is a general understanding of primary SRS for metastatic brain tumors.

High Toxoplasma gondii Seropositivity among Brain Tumor Patients in Korea

  • Jung, Bong-Kwang;Song, Hyemi;Kim, Min-Jae;Cho, Jaeeun;Shin, Eun-Hee;Chai, Jong-Yil
    • Parasites, Hosts and Diseases
    • /
    • 제54권2호
    • /
    • pp.201-204
    • /
    • 2016
  • Toxoplasma gondii is an intracellular protozoan that can modulate the environment of the infected host. An unfavorable environment modulated by T. gondii in the brain includes tumor microenvironment. Literature has suggested that T. gondii infection is associated with development of brain tumors. However, in Korea, epidemiological data regarding this correlation have been scarce. In this study, in order to investigate the relationship between T. gondii infection and brain tumor development, we investigated the seroprevalence of T. gondii among 93 confirmed brain tumor patients (various histological types, including meningioma and astrocytoma) in Korea using ELISA. The results revealed that T. gondii seropositivity among brain tumor patients (18.3%) was significantly (P<0.05) higher compared with that of healthy controls (8.6%). The seropositivity of brain tumor patients showed a significant age-tendency, i.e., higher in younger age group, compared with age-matched healthy controls (P<0.05). In conclusion, this study supports the close relationship between T. gondii infection and incidence of brain tumors.

Revolutionizing Brain Tumor Segmentation in MRI with Dynamic Fusion of Handcrafted Features and Global Pathway-based Deep Learning

  • Faizan Ullah;Muhammad Nadeem;Mohammad Abrar
    • KSII Transactions on Internet and Information Systems (TIIS)
    • /
    • 제18권1호
    • /
    • pp.105-125
    • /
    • 2024
  • Gliomas are the most common malignant brain tumor and cause the most deaths. Manual brain tumor segmentation is expensive, time-consuming, error-prone, and dependent on the radiologist's expertise and experience. Manual brain tumor segmentation outcomes by different radiologists for the same patient may differ. Thus, more robust, and dependable methods are needed. Medical imaging researchers produced numerous semi-automatic and fully automatic brain tumor segmentation algorithms using ML pipelines and accurate (handcrafted feature-based, etc.) or data-driven strategies. Current methods use CNN or handmade features such symmetry analysis, alignment-based features analysis, or textural qualities. CNN approaches provide unsupervised features, while manual features model domain knowledge. Cascaded algorithms may outperform feature-based or data-driven like CNN methods. A revolutionary cascaded strategy is presented that intelligently supplies CNN with past information from handmade feature-based ML algorithms. Each patient receives manual ground truth and four MRI modalities (T1, T1c, T2, and FLAIR). Handcrafted characteristics and deep learning are used to segment brain tumors in a Global Convolutional Neural Network (GCNN). The proposed GCNN architecture with two parallel CNNs, CSPathways CNN (CSPCNN) and MRI Pathways CNN (MRIPCNN), segmented BraTS brain tumors with high accuracy. The proposed model achieved a Dice score of 87% higher than the state of the art. This research could improve brain tumor segmentation, helping clinicians diagnose and treat patients.

Primary Cerebellar Hodgkin's Lymphoma

  • Hwang, Chul-Yoon;Song, Young-Jin;Kim, Dae-Chul;Choi, Sun-Seob;Choi, Young-Min;Kim, Ki-Uk
    • Journal of Korean Neurosurgical Society
    • /
    • 제42권2호
    • /
    • pp.149-152
    • /
    • 2007
  • Authors report a very rare case of primary Hodgkin's lymphoma limited to the cerebellum. A 64-year-old female patient presented with headache, nausea, and vomiting. Magnetic resonance imaging of the brain revealed a nodular enhancing mass in the left cerebellar hemisphere. Tumor was removed totally with retromastoid suboccipital approach. Diagnosis was Hodgkin's lymphoma of mixed cellularity type, consisting of a dense mixed inflammatory infiltrate containing scattered large atypical mononuclear Hodgkin's cell and multinucleated Reed-Sternberg cells. Systemic work-up for the Hodgkin's lymphoma was followed with negative result. Postoperative radiation therapy was given and the patient is disease-free at 16 months after the operation.

Two-Day Fraction Gamma Knife Radiosurgery for Large Brain Metastasis

  • Joo-Hwan Lee;In-Young Kim;Shin Jung;Tae-Young Jung;Kyung-Sub Moon;Yeong-Jin Kim;Sue-Jee Park;Sa-Hoe Lim
    • Journal of Korean Neurosurgical Society
    • /
    • 제67권5호
    • /
    • pp.560-567
    • /
    • 2024
  • Objective : We investigated how treating large brain metastasis (LBM) using 2-day fraction Gamma Knife radiosurgery (GKRS) affects tumor control and patient survival. A prescription dose of 10.3 Gy was applied for 2 consecutive days, with a biologically effective dose equivalent to a tumor single-fraction dose of 16.05 Gy and a brain single-fraction dose of 15.12 Gy. Methods : Between November 2017 and December 2021, 42 patients (mean age, 68.3 years; range, 50-84 years; male, 29 [69.1%]; female, 13 [30.9%]) with 44 tumors underwent 2-day fraction GKRS to treat large volume brain metastasis. The main cancer types were non-small cell lung cancer (n=16), small cell lung cancer (n=7), colorectal cancer (n=7), breast cancer (n=3), gastric cancer (n=2), and other cancers (n=7). Twenty-one patients (50.0%) had a single LBM, 19 (46.3%) had a single LBM and other metastases, and two had two (4.7%) large brain metastases. At the time of the 2-day fraction GKRS, the tumors had a mean volume of 23.1 mL (range, 12.5-67.4). On each day, radiation was administered at a dose of 10.3 Gy, mainly using a 50% isodose-line. Results : We obtained clinical and magnetic resonance imaging follow-up data for 34 patients (81%) with 35 tumors, who had undergone 2-day fraction GKRS. These patients did not experience acute or late radiation-induced complications during follow-up. The median and mean progression-free survival (PFS) periods were 188 and 194 days, respectively. The local control rates at 6, 9, and 12 months were 77%, 40%, and 34%, respectively. The prognostic factors related to PFS were prior radiotherapy (p=0.019) and lung cancer origin (p=0.041). Other factors such as tumor volumes, each isodose volumes, and peri-GKRS systemic treatment were not significantly related to PFS. The overall survival period of the 44 patients following repeat stereotactic radiosurgery (SRS) ranged from 15-878 days (median, 263±38 days; mean, 174±43 days) after the 2-day fraction GKRS. Eight patients (18.2%) were still alive. Conclusion : Considering the unsatisfactory tumor control, a higher prescription dose should be needed in this procedure as a salvage management. Moreover, in the treatment for LBM with fractionated SRS, using different isodoses and prescription doses at the treatment planning for LBMs should be important. However, this report might be a basic reference with the same fraction number and prescription dose in the treatment for LBMs with frame-based SRS.

Glioblastoma Cellular Origin and the Firework Pattern of Cancer Genesis from the Subventricular Zone

  • Yoon, Seon-Jin;Park, Junseong;Jang, Dong-Su;Kim, Hyun Jung;Lee, Joo Ho;Jo, Euna;Choi, Ran Joo;Shim, Jin-Kyung;Moon, Ju Hyung;Kim, Eui-Hyun;Chang, Jong Hee;Lee, Jeong Ho;Kang, Seok-Gu
    • Journal of Korean Neurosurgical Society
    • /
    • 제63권1호
    • /
    • pp.26-33
    • /
    • 2020
  • Glioblastoma (GBM) is a disease without any definite cure. Numerous approaches have been tested in efforts to conquer this brain disease, but patients invariably experience recurrence or develop resistance to treatment. New surgical tools, carefully chosen samples, and experimental methods are enabling discoveries at single-cell resolution. The present article reviews the cell-of-origin of isocitrate dehydrogenase (IDH)-wildtype GBM, beginning with the historical background for focusing on cellular origin and introducing the cancer genesis patterned on firework. The authors also review mutations associated with the senescence process in cells of the subventricular zone (SVZ), and biological validation of somatic mutations in a mouse SVZ model. Understanding GBM would facilitate research on the origin of other cancers and may catalyze the development of new management approaches or treatments against IDH-wildtype GBM.